Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC.CSBR · Entity 7013 | Director | January 19, 2021 | February 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHAMPIONS ONCOLOGY, INC.
Report date January 19, 2021 · Filed February 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 70,147 |
Reported balance
After 2021-01-19 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2021-01-19 · Exercise / conversion · Acquired 10,000 · Balance 70,147 |
| Common StockSEC Table I · non-derivative | Direct | 80,147 |
Reported balance
After 2021-01-19 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2021-01-19 · Exercise / conversion · Acquired 10,000 · Balance 80,147 |
| Common StockSEC Table I · non-derivative | Direct | 90,147 |
Reported balance
After 2021-01-19 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2021-01-19 · Exercise / conversion · Acquired 10,000 · Balance 90,147 |
| Common StockSEC Table I · non-derivative | Direct | 81,274 |
Reported balance
After 2021-01-19 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2021-01-19 · Tax withholding · Acquired 8,873 · Balance 81,274 F1: Represents a "net exercise" of outstanding stock options. The shares were withheld by Champions Oncology, Inc. for payment of the exercise price based on the market price of Champions Oncology, Inc. common stock on January 19,2021. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2021-11-01 | Direct | 0 |
Reported balance
After 2021-01-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-01-19 · Exercise / conversion · Disposed 10,000 · Balance 0 F2: The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2016, February 1, 2017, May 1, 2017 and August 1, 2017 respectively. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.21 · Expires 2022-10-31 | Direct | 0 |
Reported balance
After 2021-01-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-01-19 · Exercise / conversion · Disposed 10,000 · Balance 0 F3: The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2017, February 1, 2018, May 1, 2018 and August 1, 2018, respectively. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.43 · Expires 2024-11-04 | Direct | 0 |
Reported balance
After 2021-01-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-01-19 · Exercise / conversion · Disposed 10,000 · Balance 0 F4: The options vest and are exercisable over a twelve month period, with vesting to occur on November 4, 2019, February 4, 2020, May 4, 2020 and August 4, 2020, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a "net exercise" of outstanding stock options. The shares were withheld by Champions Oncology, Inc. for payment of the exercise price based on the market price of Champions Oncology, Inc. common stock on January 19,2021.
F2: The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2016, February 1, 2017, May 1, 2017 and August 1, 2017 respectively.
F3: The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2017, February 1, 2018, May 1, 2018 and August 1, 2018, respectively.
F4: The options vest and are exercisable over a twelve month period, with vesting to occur on November 4, 2019, February 4, 2020, May 4, 2020 and August 4, 2020, respectively.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2021 Filed Feb 8, 2021 21:46 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | Exercise / conversionOption to purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001628280-21-001615 · wf-form4_161282076952132.xml · derivative · entry 7 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 4, 2019, February 4, 2020, May 4, 2020 and August 4, 2020, respectively. Read SEC document |
| January 19, 2021 Filed Feb 8, 2021 21:46 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | Exercise / conversionOption to purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001628280-21-001615 · wf-form4_161282076952132.xml · derivative · entry 6 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2017, February 1, 2018, May 1, 2018 and August 1, 2018, respectively. Read SEC document |
| January 19, 2021 Filed Feb 8, 2021 21:46 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | Exercise / conversionOption to purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001628280-21-001615 · wf-form4_161282076952132.xml · derivative · entry 5 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2016, February 1, 2017, May 1, 2017 and August 1, 2017 respectively. Read SEC document |
| January 19, 2021 Filed Feb 8, 2021 21:46 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | Tax withholdingCommon Stock | 8,873 | $11.53 | $102,305.69 |
DisclosureSEC source: 0001628280-21-001615 · wf-form4_161282076952132.xml · nonDerivative · entry 4 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,274 F1 · kind: Represents a "net exercise" of outstanding stock options. The shares were withheld by Champions Oncology, Inc. for payment of the exercise price based on the market price of Champions Oncology, Inc. common stock on January 19,2021. Read SEC document |
| January 19, 2021 Filed Feb 8, 2021 21:46 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | Exercise / conversionCommon Stock | 10,000 | $5.43 | $54,300.00 |
DisclosureSEC source: 0001628280-21-001615 · wf-form4_161282076952132.xml · nonDerivative · entry 3 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2021 Filed Feb 8, 2021 21:46 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | Exercise / conversionCommon Stock | 10,000 | $3.21 | $32,100.00 |
DisclosureSEC source: 0001628280-21-001615 · wf-form4_161282076952132.xml · nonDerivative · entry 2 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2021 Filed Feb 8, 2021 21:46 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | Exercise / conversionCommon Stock | 10,000 | $1.59 | $15,900.00 |
DisclosureSEC source: 0001628280-21-001615 · wf-form4_161282076952132.xml · nonDerivative · entry 1 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 22:00 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 2,500 | $11.96 Strike: $11.96 | $29,900.00 |
DisclosureSEC source: 0001628280-20-017365 · wf-form4_160763758579660.xml · derivative · entry 1 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2025-12-08 F1 · derivative.exercise_date: The options vest immediately at the grant date. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 22:15 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 10,000 | $5.43 Strike: $5.43 | $54,300.00 |
DisclosureSEC source: 0001628280-19-013530 · wf-form4_157307852453753.xml · derivative · entry 1 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2024-11-03 F1 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 4, 2019, February 4, 2020, May 4, 2020 and August 4, 2020, respectively. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 16:45 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 10,000 | $12.73 Strike: $12.73 | $127,300.00 |
DisclosureSEC source: 0001628280-18-013560 · wf-form4_154143632468957.xml · derivative · entry 1 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2023-11-01 F1 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2018, February 1, 2019, May 1, 2019 and August 1, 2019, respectively. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 21:07 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 10,000 | $3.21 Strike: $3.21 | $32,100.00 |
DisclosureSEC source: 0001628280-17-011455 · wf-form4_151060724600611.xml · derivative · entry 1 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2022-10-31 F1 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 8, 2017, February 1, 2018, May 1, 2018 and August 1, 2018, respectively. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 17:27 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantStock Options · Derivative | 10,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001628280-16-020690 · wf-form4_147819403060591.xml · derivative · entry 1 Poliakoff Abba David · CIK 0001423066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2021-10-31 F1 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2016, February 1, 2017, May 1, 2017 and August 1, 2017, respectively. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.